Merus Highlights the Preclinical Results from the Study of Zenocutuzumab for Cancer Treatment at the AACR 2024
Shots:
- Merus highlighted preclinical results of zenocutuzumab, HER2 × HER3 bispecific antibody, in 28 patient-derived xenograft (PDX) NRG1 expressing cancer models with 21 tumor types where zenocutuzumab demonstrated tumor growth inhibition among 7/28 PDX models
- In preclinical study, zenocutuzumab inhibited the N87 gastric cancer & SKBR-3 breast cancer cell lines’ proliferation at high concentrations of NRG1. It further inhibited the NRG1-amplified HCC95 lung cancer cell line proliferation, blocking the signals controlling cell growth & survival
- The above results confirmed the efficacy of zenocutuzumab tumor cell destruction in vitro and in vivo among cancer models expressing NRG1
Ref: Merus | Image: Merus
Related News:- Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
